ClinicalTrials.gg
CompletedNCT06596668Updated Mar 18, 2025

Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

A Phase 1 interventional study of bomedemstat and carbamazepine in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Researchers have designed a study medicine called bomedemstat (MK-3543) as a new way to treat certain rare blood diseases.

The purpose of this study is to learn what happens to bomedemstat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to bomedemstat in the body when it is given alone and after multiple doses of another medicine called carbamazepine (CBZ).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months before entering the study.
  • (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2
  • Medically healthy with no medical history

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • History or presence of any of the following:

    • Seizures
    • Negative reactions in the blood system to any drugs
    • Depression, unusual changes in mood or behavior or suicidal thoughts or behavior
  • History of cancer
  • Regular user of cannabis products within 6 months before entering the study.
  • Unable to stop using or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days before entering the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Bomedemstat + Carbamazepine

    A single dose of bomedemstat will be administered On Day 1 of Period 1. There will be a washout of 7 days between bomedemstat dosing in Period 1 and the first carbamazepine (CBZ) dose in Period 2. In Period 2, CBZ will be administered twice daily (BID) for 17 consecutive days, with a single dose of bomedemstat coadministered with the morning dose on Day 14.

    Drug: bomedemstat · Drug: carbamazepine

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration versus time curve from 0 to infinity (AUC0-inf) of bomedemstat

    AUC0-inf for bomedemstat in plasma will be determined

    Time frame: Predose and at designated timepoints up to 168 hours postdose

Secondary outcomes

  1. Number of participants who experience one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 66 days

  2. Number of participants who discontinue study treatment due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 25 days

  3. Area under the concentration versus time curve from 0 to the time of the last quantifiable sample (AUC0-last) of bomedemstat

    AUC0-last for bomedemstat in plasma will be determined

    Time frame: Predose and at designated timepoints up to 168 hours postdose

  4. Area under the concentration versus time curve from 0 to 24 hours after dosing (AUC0-24) of bomedemstat

    AUC0-24 for bomedemstat in plasma will be determined

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  5. Maximum observed concentration (Cmax) of bomedemstat

    Cmax for bomedemstat in plasma will be determined

    Time frame: Predose and at designated timepoints up to 168 hours postdose

  6. Maximum observed concentration 24 hours after dosing (C24) bomedemstat

    Cmax for bomedemstat in plasma will be determined

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  7. Time to maximum concentration (Tmax) of bomedemstat

    Tmax for bomedemstat in plasma will be determined

    Time frame: Predose and at designated timepoints up to 168 hours postdose

  8. Apparent terminal half-life (t1/2) of bomedemstat

    t1/2 for bomedemstat in plasma will be determined

    Time frame: Predose and at designated timepoints up to 168 hours postdose

  9. Apparent clearance (CL/F) of bomedemstat

    CL/F for bomedemstat in plasma will be determined

    Time frame: Predose and at designated timepoints up to 168 hours postdose

  10. Apparent volume of distribution during terminal phase (Vz/F) of bomedemstat in plasma

    Vz/F for bomedemstat in plasma will be determined

    Time frame: Predose and at designated timepoints up to 168 hours postdose

07

Study locations

1 site
  • Celerion, Inc. ( Site 0001)
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Feb 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2024
First posted
Sep 19, 2024
StartActual
Oct 2, 2024
Primary completionActual
Feb 5, 2025
CompletionActual
Mar 11, 2025
Last update
Mar 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06596668
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 2, 2024
Primary completion
Feb 5, 2025
Completion
Mar 11, 2025
Last update
Mar 18, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bomedemstat

Start the discussion